Skip to main content

Branded

  • NCPA among industry associations rejecting proposal to reschedule hydrocodone

    ALEXANDRIA, Va. — The National Community Pharmacists Association last week called for the rejection of a proposal made by Sens. Joe Manchin, D-W.Va., and Mark Kirk, R.-Ill., to reschedule Vicodin and other hydrocodone-containing products from Schedule III to Schedule II of the Controlled Substances Act.

  • FDA delays approval of GSK vaccine

    LONDON — The Food and Drug Administration has declined to approve a bird flu vaccine made by GlaxoSmithKline due to an administrative issue, the drug maker said.

    GSK said it received a complete response letter from the FDA for its vaccine for pandemic influenza A virus monovalent adjuvanted candidate vaccine, also known as Q-Pan H5N1. The FDA issues a complete response letter when it needs additional time to review a drug application for approval.

  • Safe Kids Worldwide publishes new report outlining medicine poisoning risk among children

    WASHINGTON — According to the new report “An In-Depth Look at Keeping Young Children Safe Around Medicines,” released last week by Safe Kids Worldwide, 7-of-10 emergency department visits for medicine poisonings are due to curious young children getting into their grandparent’s or mother’s medicine that was left within reach.

  • Drug makers ramp up treatments for chronic conditions in the elderly, PhRMA report finds

    WASHINGTON — More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

  • Lilly, BI apply for diabetes drug approval

    RIDGEFIELD, Conn. — Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said Monday.

    BI and Lilly announced the submission of a regulatory application to the Food and Drug Administration for empagliflozin. The drug belongs to a new drug class known as SGLT2 inhibitors, which work by removing excess glucose through the urine by blocking its reabsorption in the kidneys. The companies are testing the drug in a late-stage clinical trial for which they plan to enroll 14,500 patients.

  • Supreme Court hears patent-settlement case

    NEW YORK — The Supreme Court heard arguments Monday in a case that could determine the future of generic drugs in America.

    The case, Federal Trade Commission v. Actavis, marks the latest attempt by federal authorities to put an end to what they say are deals between branded and generic drug companies that delay release of generic drugs to consumers.

  • CDC: Of the 105 flu-related pediatric deaths this season, 9-in-10 did not get a flu shot

    ATLANTA — An early look at this season’s reports indicates that about 90% of flu-related pediatric deaths occurred in children who had not received a flu vaccination this season, the Centers for Disease Control and Prevention reported Friday. 

    The number of influenza-associated pediatric deaths reported to the CDC during the current season surpassed 100 as an additional 6 deaths were reported in FluView last week. To date, this brings the total number of influenza-associated pediatric deaths reported to the CDC to 105 for the 2012-2013 season.

  • FDA approves Novartis antibacterial treatment for cystic fibrosis

    EAST HANOVER, N.J. — The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

    Swiss drug maker Novartis announced the approval of Tobi Podhaler (tobramycin inhalation powder) for managing cystic fibrosis patients with Pseudomonas aeruginosa, or Pa bacteria, in the lungs.

X
This ad will auto-close in 10 seconds